Cargando…

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902336/ https://www.ncbi.nlm.nih.gov/pubmed/29666841 http://dx.doi.org/10.1212/NXI.0000000000000462

Ejemplares similares

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017)

Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal
por: Koska, Valeria, et al.
Publicado: (2021)

Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder
por: Lin, Wei, et al.
Publicado: (2023)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations
por: Barry, Brian, et al.
Publicado: (2019)

Severe rebound disease activity after fingolimod withdrawal in a pregnant woman with multiple sclerosis managed with rituximab: A case study
por: Canibaño, Beatriz, et al.
Publicado: (2019)

Fingolimod: Rebound effect in the form of exacerbation of COVID-19: case report
Publicado: (2021)

Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption
por: De Masi, Roberto, et al.
Publicado: (2015)

Sensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis
por: Naser Moghadasi, Abdoreza, et al.
Publicado: (2020)

Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases
por: Schmidt, Stephan, et al.
Publicado: (2019)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

Lymphocyte recovery after fingolimod discontinuation in patients with MS
por: Nagy, Sara, et al.
Publicado: (2020)

Narrative review based on fingolimod therapy in pediatric MS
por: Piri Cinar, Bilge, et al.
Publicado: (2023)

Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer
por: Lam, Clarissa, et al.
Publicado: (2023)

Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2023)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients
por: Serpero, Laura D., et al.
Publicado: (2013)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Different MRI patterns in MS worsening after stopping fingolimod
por: Lapucci, Caterina, et al.
Publicado: (2019)

Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development
por: Lerner, Alicja, et al.
Publicado: (2019)

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
por: Hill, Alison L., et al.
Publicado: (2017)

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
Publicado: (2016)

A dramatic, objective antiandrogen withdrawal response: case report and review of the literature
por: Lau, Yiu-Keung, et al.
Publicado: (2008)

Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study
por: Nishiyama, Shuhei, et al.
Publicado: (2017)

Correction to: Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic
por: Brown, Brandon, et al.
Publicado: (2019)

Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients
por: Webb, M J, et al.
Publicado: (2023)

Tumefactive demyelination with a transient appearance of oligoclonal bands in MS under fingolimod
por: Okada, Kazumasa, et al.
Publicado: (2018)

HSV-2–related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MS
por: Ikumi, Kazuhiro, et al.
Publicado: (2016)

Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center
por: Roux, Thomas, et al.
Publicado: (2017)

Correction: Prophylactic versus Therapeutic Fingolimod: Restoration of Presynaptic Defects in Mice Suffering from Experimental Autoimmune Encephalomyelitis
por: Bonfiglio, Tommaso, et al.
Publicado: (2023)

Correction to: Decomposing PM(2.5) air pollution rebounds in Northern China before COVID‑19
por: Dong, Changgui, et al.
Publicado: (2022)

Intermittent Atrioventricular Block following Fingolimod Initiation
por: Gialafos, E., et al.
Publicado: (2014)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Correction to: Prevention of alcohol withdrawal seizure recurrence and treatment of other alcohol withdrawal symptoms in the emergency department: a rapid review
por: Koh, Justin Jek-Kahn, et al.
Publicado: (2022)

Beneficial effects of fingolimod in MS patients with high serum Sema4A levels
por: Koda, Toru, et al.
Publicado: (2018)

Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS
por: Fox, Edward J., et al.
Publicado: (2019)

Correction: Polypeptone Induces Dramatic Cell Lysis in ura4 Deletion Mutants of Fission Yeast
por: Matsuo, Yuzy, et al.
Publicado: (2013)

The endosymbiont Wolbachia rebounds following antibiotic treatment
por: Gunderson, Emma L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4fk2chjvsppfg8688j31ktvm3t